{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:50:01Z","timestamp":1790725801689,"version":"4.1.0"},"reference-count":50,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.3201\/eid2703.203482","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T03:59:55Z","timestamp":1614052795000},"page":"779-788","source":"Crossref","is-referenced-by-count":54,"title":["Fluconazole-Resistant <i>Candida glabrata<\/i> Bloodstream Isolates, South Korea, 2008\u20132018"],"prefix":"10.3201","volume":"27","author":[{"given":"Eun Jeong","family":"Won","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Na","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongeun","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Gyo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Uh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taek Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Ah","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Yeob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MCC.0b013e32833e84d2","article-title":"Epidemiology of invasive candidiasis.","volume":"16","author":"Arendrup","year":"2010","journal-title":"Curr Opin Crit Care"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-2","doi-asserted-by":"publisher","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment.","volume":"216","author":"Arendrup","year":"2017","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-3","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1128\/AAC.01763-15","article-title":"Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study.","volume":"60","author":"Jensen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-4","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016.","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/jac\/dkx047","article-title":"Changing epidemiology of candidaemia in Australia.","volume":"72","author":"Chapman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/mmy\/myv114","article-title":"Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region.","volume":"54","author":"Tan","year":"2016","journal-title":"Med Mycol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-7","doi-asserted-by":"publisher","first-page":"e1000268","DOI":"10.1371\/journal.ppat.1000268","article-title":"Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.","volume":"5","author":"Ferrari","year":"2009","journal-title":"PLoS Pathog"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-8","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1128\/AAC.50.4.1384-1392.2006","article-title":"Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants.","volume":"50","author":"Tsai","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-9","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1128\/AAC.06253-11","article-title":"Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.","volume":"56","author":"Hull","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fcimb.2013.00074","article-title":"Interactions between copy number and expression level of genes involved in fluconazole resistance in Candida glabrata.","volume":"3","author":"Abbes","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-11","doi-asserted-by":"publisher","first-page":"e00099","DOI":"10.1128\/mSphere.00099-18","article-title":"Construction and use of a recyclable marker to examine the role of major facilitator superfamily protein members in Candida glabrata drug resistance phenotypes.","volume":"3","author":"Vu","year":"2018","journal-title":"MSphere"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-12","doi-asserted-by":"publisher","first-page":"e17589","DOI":"10.1371\/journal.pone.0017589","article-title":"Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata.","volume":"6","author":"Ferrari","year":"2011","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-13","doi-asserted-by":"publisher","first-page":"e00153","DOI":"10.1128\/AAC.00153-18","article-title":"Profiling of PDR1 and MSH2 in Candida glabrata bloodstream isolates from a multicenter study in China.","volume":"62","author":"Hou","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-14","doi-asserted-by":"publisher","first-page":"e02503","DOI":"10.1128\/AAC.02503-18","article-title":"Low level of antifungal resistance in Iranian isolates of Candida glabrata recovered from blood samples in a multicenter study from 2015 to 2018 and potential prognostic values of genotyping and sequencing of PDR1.","volume":"63","author":"Arastehfar","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fmicb.2017.00005","article-title":"Identification and antifungal susceptibility profiles of Candida nivariensis and Candida bracarensis in a multi-center Chinese collection of yeasts.","volume":"8","author":"Hou","year":"2017","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-16","unstructured":"Clinical and Laboratory Standards Institute. M27 reference method for broth dilution antifungal susceptibility testing of yeasts. 4th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2017."},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-17","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of Yeasts. 1st ed. CLSI supplement M60. Wayne (PA): Clinical and Laboratory Standards Institute; 2017."},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-18","unstructured":"Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing. 2nd ed. CLSI supplement M59. Wayne (PA): Clinical and Laboratory Standards Institute; 2018."},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-19","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3389\/fmicb.2019.01585","article-title":"Clinical and laboratory development of echinocandin resistance in Candida glabrata: molecular characterization.","volume":"10","author":"Rivero-Menendez","year":"2019","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-21","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3389\/fmicb.2018.01523","article-title":"Multilocus sequence typing (MLST) genotypes of Candida glabrata bloodstream isolates in Korea: association with antifungal resistance, mutations in mismatch repair gene (Msh2), and clinical outcomes.","volume":"9","author":"Byun","year":"2018","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-22","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1086\/597108","article-title":"Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features.","volume":"48","author":"Kim","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/jac\/dks480","article-title":"Mortality in patients with early- or late-onset candidaemia.","volume":"68","author":"De Rosa","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1086\/514193","article-title":"Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.","volume":"177","author":"Nguyen","year":"1998","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-25","doi-asserted-by":"publisher","first-page":"11128","DOI":"10.1038\/ncomms11128","article-title":"Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.","volume":"7","author":"Healey","year":"2016","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1570-0232(02)00668-2","article-title":"Identification of two proteins induced by exposure of the pathogenic fungus Candida glabrata to fluconazole.","volume":"782","author":"Niimi","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1128\/AAC.49.2.668-679.2005","article-title":"Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.","volume":"49","author":"Sanguinetti","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-28","doi-asserted-by":"publisher","first-page":"e0118770","DOI":"10.1371\/journal.pone.0118770","article-title":"Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage.","volume":"10","author":"Won","year":"2015","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-29","doi-asserted-by":"publisher","first-page":"e00577","DOI":"10.1128\/JCM.00577-18","article-title":"Five-year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF\u2013NET) Study.","volume":"56","author":"Xiao","year":"2018","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-30","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3389\/fmicb.2017.00880","article-title":"Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (August 2009 to July 2014): a multi-center study.","volume":"8","author":"Hou","year":"2017","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jiac.2018.09.016","article-title":"Changing epidemiology of non-albicans candidemia in Korea.","volume":"25","author":"Ko","year":"2019","journal-title":"J Infect Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijid.2019.03.039","article-title":"Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents.","volume":"83","author":"Choi","year":"2019","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijantimicag.2009.02.021","article-title":"Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.","volume":"34","author":"Ruan","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1086\/599039","article-title":"Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.","volume":"48","author":"Horn","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ajic.2010.02.016","article-title":"Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections.","volume":"38","author":"Lee","year":"2010","journal-title":"Am J Infect Control"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-36","doi-asserted-by":"publisher","first-page":"e02566","DOI":"10.1128\/AAC.02566-17","article-title":"Survival in patients with Candida glabrata bloodstream infection is associated with fluconazole dose.","volume":"62","author":"Eschenauer","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.diagmicrobio.2018.05.001","article-title":"Impact of high MIC of fluconazole on outcomes of Candida glabrata bloodstream infection: a retrospective multicenter cohort study.","volume":"92","author":"Ko","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1439-0507.2011.02044.x","article-title":"Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008).","volume":"55","author":"Tortorano","year":"2012","journal-title":"Mycoses"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010).","volume":"40","author":"Lortholary","year":"2014","journal-title":"Intensive Care Med"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-40","doi-asserted-by":"publisher","first-page":"e101510","DOI":"10.1371\/journal.pone.0101510","article-title":"Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.","volume":"9","author":"Pfaller","year":"2014","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-41","doi-asserted-by":"publisher","first-page":"e00195","DOI":"10.1128\/AAC.00195-18","article-title":"Absence of azole or echinocandin resistance in Candida glabrata isolates in India despite background prevalence of strains with defects in the DNA mismatch repair pathway.","volume":"62","author":"Singh","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-42","doi-asserted-by":"publisher","first-page":"e01876","DOI":"10.1128\/AAC.01876-18","article-title":"MSH2 gene point mutations are not antifungal resistance markers in Candida glabrata.","volume":"63","author":"Bordallo-Cardona","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-43","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.3389\/fmicb.2018.02946","article-title":"Whole genome sequencing of Australian Candida glabrata isolates reveals genetic diversity and novel sequence types.","volume":"9","author":"Biswas","year":"2018","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-44","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2147\/IDR.S202058","article-title":"Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China.","volume":"12","author":"Yao","year":"2019","journal-title":"Infect Drug Resist"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-45","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.3389\/fmicb.2016.02173","article-title":"Azole antifungal resistance in Candida albicans and emerging non\u2013albicans Candida species.","volume":"7","author":"Whaley","year":"2017","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jgar.2019.01.006","article-title":"Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients.","volume":"17","author":"Tantivitayakul","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-47","doi-asserted-by":"publisher","first-page":"142","DOI":"10.15698\/mic2019.03.670","article-title":"Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection.","volume":"6","author":"Pais","year":"2019","journal-title":"Microb Cell"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-48","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/myc.12756","article-title":"CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.","volume":"61","author":"Ni","year":"2018","journal-title":"Mycoses"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-49","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/cmi.12091","article-title":"Two unlike cousins: Candida albicans and C. glabrata infection strategies.","volume":"15","author":"Brunke","year":"2013","journal-title":"Cell Microbiol"},{"key":"key-10.3201\/eid2703.203482-202102222256-R-2-50","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/AAC.01128-10","article-title":"Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.","volume":"55","author":"Lortholary","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/27\/3\/20-3482_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:50:44Z","timestamp":1732989044000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/27\/3\/20-3482_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2703.203482","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}